Stock comparison
Moderna
MRNA$22.98BHealthcare Market cap, Sector
Pro Medicus Limited
PME.AX$16.79BHealthcare Market cap, Sector
Overall winner
Pro Medicus Limited
MRNA 07 PME.AX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
MRNA0wins
7winsPME.AX
19F
B78
45D
A90
25F
A98
2F
A100
0F
B84
17F
A91
17F
A96
Side-by-side metrics
| Metric | MRNA | PME.AX |
|---|---|---|
| Market cap | Winner: $22.98B | $16.79B |
| P/E (TTM) | Winner: - | 147.6x |
| EV/EBIT | Winner: - | 106.8x |
| ROIC (TTM) | -37.32% | 42.56% Winner |
| Gross margin | -13.89% | 99.85% Winner |
| Net margin | -143.55% | 54.12% Winner |
| Revenue CAGR 5y | -42.46% | 31.61% Winner |
| EPS CAGR 5y | - | 37.34% |
| Debt / Equity | 0.2x | 0.0x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MRNA leads on
- EV/EBIT-vs 106.8x+106%
- P/E (TTM)-vs 147.6x+104%
- Market cap$22.98Bvs $16.79B+27%
PME.AX leads on
- ROIC (TTM)42.56%vs -37.32%+188%
- Revenue CAGR 5y31.61%vs -42.46%+174%
- Net margin54.12%vs -143.55%+138%
- Gross margin99.85%vs -13.89%+114%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.